XML 23 R11.htm IDEA: XBRL DOCUMENT
v3.23.3

Restructuring, Impairment, and Related Charges, Net | 6 Months Ended
--- | ---
Sep. 30, 2023
Restructuring and Related Activities [Abstract] |
Restructuring, Impairment, and Related Charges, Net | Restructuring, Impairment, and Related Charges, Net The Company recorded restructuring, impairment, and related charges, net of $28 million and $30 million for the three months ended September 30, 2023 and 2022, respectively, and $80 million and $53 million for the six months ended September 30, 2023 and 2022, respectively. These charges were included in “Restructuring, impairment, and related charges, net” in the Condensed Consolidated Statements of Operations. Restructuring Initiatives During the fourth quarter of fiscal 2023, the Company approved a broad set of initiatives to drive operational efficiencies and increase cost optimization efforts, with the intent of simplifying its infrastructure and realizing long-term sustainable growth. These initiatives include headcount reductions and the exit or downsizing of certain facilities. The Company anticipates total charges of approximately $125 million across its RxTS and U.S. Pharmaceutical segments as well as Corporate, consisting primarily of employee severance and other employee-related costs, facility and other exit-related costs, as well as long-lived asset impairments. Of this amount, $99 million of cumulative charges were recorded through September 30, 2023. For the three and six months ended September 30, 2023, the Company recorded charges of $3 million and $39 million related to this program, respectively, which primarily includes real estate and other related asset impairments and facility costs within Corporate. This restructuring program is anticipated to be substantially complete by the end of fiscal 2024. Restructuring, impairment, and related charges, net for the three months ended September 30, 2023 and 2022 consisted of the following:
| Three Months Ended September 30, 2023
(In millions) | U.S. Pharmaceutical |  | Prescription Technology Solutions (1) |  | Medical-Surgical Solutions |  | International |  | Corporate |  | Total
Severance and employee-related costs, net | $ | 8 |  |  | $ | — |  |  | $ | — |  |  | $ | 2 |  |  | $ | — |  |  | $ | 10 |
Exit and other-related costs (2) | 1 |  |  | 3 |  |  | 4 |  |  | 4 |  |  | 6 |  |  | 18 |
Asset impairments and accelerated depreciation | — |  |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Total | $ | 9 |  |  | $ | 3 |  |  | $ | 4 |  |  | $ | 6 |  |  | $ | 6 |  |  | $ | 28 |
(1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s technology solutions. (2)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.
| Three Months Ended September 30, 2022
(In millions) | U.S. Pharmaceutical |  | Prescription Technology Solutions |  | Medical-Surgical Solutions |  | International |  | Corporate |  | Total
Severance and employee-related costs, net | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 2 |  |  | $ | (5) |  |  | $ | (3) |
Exit and other-related costs (1) | — |  |  | 1 |  |  | 1 |  |  | 6 |  |  | 14 |  |  | 22 |
Asset impairments and accelerated depreciation | 3 |  |  | 6 |  |  | — |  |  | 1 |  |  | 1 |  |  | 11 |
Total | $ | 3 |  |  | $ | 7 |  |  | $ | 1 |  |  | $ | 9 |  |  | $ | 10 |  |  | $ | 30 |
(1)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred. Restructuring, impairment, and related charges, net, for the six months ended September 30, 2023 and 2022 consisted of the following:
| Six Months Ended September 30, 2023
(In millions) | U.S. Pharmaceutical |  | Prescription Technology Solutions (1) |  | Medical-Surgical Solutions |  | International |  | Corporate (1) |  | Total
Severance and employee-related costs, net | $ | 9 |  |  | $ | — |  |  | $ | — |  |  | $ | 2 |  |  | $ | 1 |  |  | $ | 12 |
Exit and other-related costs (2) | 2 |  |  | 5 |  |  | 6 |  |  | 9 |  |  | 18 |  |  | 40 |
Asset impairments and accelerated depreciation | — |  |  | — |  |  | — |  |  | 1 |  |  | 27 |  |  | 28 |
Total | $ | 11 |  |  | $ | 5 |  |  | $ | 6 |  |  | $ | 12 |  |  | $ | 46 |  |  | $ | 80 |
(1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s technology solutions. (2)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.
| Six Months Ended September 30, 2022
(In millions) | U.S. Pharmaceutical |  | Prescription Technology Solutions |  | Medical-Surgical Solutions |  | International |  | Corporate |  | Total
Severance and employee-related costs, net | $ | 3 |  |  | $ | — |  |  | $ | — |  |  | $ | 2 |  |  | $ | (6) |  |  | $ | (1) |
Exit and other-related costs (1) | 1 |  |  | 3 |  |  | 2 |  |  | 8 |  |  | 29 |  |  | 43 |
Asset impairments and accelerated depreciation | 3 |  |  | 11 |  |  | — |  |  | 1 |  |  | (4) |  |  | 11 |
Total | $ | 7 |  |  | $ | 14 |  |  | $ | 2 |  |  | $ | 11 |  |  | $ | 19 |  |  | $ | 53 |
(1)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred. The following table summarizes the activity related to the liabilities associated with the Company’s restructuring initiatives for the six months ended September 30, 2023:
(In millions) | U.S. Pharmaceutical |  | Prescription Technology Solutions |  | Medical-Surgical Solutions |  | International |  | Corporate |  | Total
Balance, March 31, 2023 (1) | $ | 15 |  |  | $ | 26 |  |  | $ | 3 |  |  | $ | 13 |  |  | $ | 35 |  |  | $ | 92 |
Restructuring, impairment, and related charges, net | 11 |  |  | 5 |  |  | 6 |  |  | 12 |  |  | 46 |  |  | 80 |
Non-cash charges | — |  |  | — |  |  | — |  |  | (1) |  |  | (27) |  |  | (28) |
Cash payments | (10) |  |  | (26) |  |  | (6) |  |  | (3) |  |  | (23) |  |  | (68) |
Other (2) | — |  |  | — |  |  | — |  |  | (10) |  |  | — |  |  | (10) |
Balance, September 30, 2023 (3) | $ | 16 |  |  | $ | 5 |  |  | $ | 3 |  |  | $ | 11 |  |  | $ | 31 |  |  | $ | 66 |
(1)As of March 31, 2023, the total reserve balance was $92 million, of which $66 million was recorded in “Other accrued liabilities” and $26 million was recorded in “Other non-current liabilities” in the Company’s Condensed Consolidated Balance Sheet. (2)Other primarily includes cumulative translation adjustments and transfers to certain other liabilities. (3)As of September 30, 2023, the total reserve balance was $66 million, of which $32 million was recorded in “Other accrued liabilities” and $34 million was recorded in “Other non-current liabilities” in the Company’s Condensed Consolidated Balance Sheet.

X
- References No definition available. + Details
Name: | us-gaap_RestructuringAndRelatedActivitiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//420/tableOfContent Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4(e)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2 + Details
Name: | us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration